Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Alzheimer’s Disease: Pipeline Review, Developer Landscape and Competitive Insights 2019 - ResearchAndMarkets.com

May 2, 2019

DUBLIN--(BUSINESS WIRE)--May 2, 2019--The “Alzheimer’s Disease: Pipeline Review, Developer Landscape and Competitive Insights” report has been added to ResearchAndMarkets.com’s offering.

Alzheimer’s disease is a neurodegenerative condition characterized by progressive memory loss, cognitive dysfunction and dementia. Currently, it is the most commonly reported neurodegenerative disorder across the world, and the sixth leading cause of death in the US. It was estimated that, in 2018, nearly 5.7 million Americans (considering all age groups) were living with Alzheimer’s disease. During the same year, Alzheimer’s disease and other dementias were projected to be responsible for a healthcare burden amounting to USD 277 billion, in the US. Considering that only a limited range of diagnosis, treatment and disease management solutions are presently available, this segment of the healthcare industry is presently faced with a pressing need for accurate diagnostic (predictive) tests and efficient treatment options that have the capability to slow the progression of the condition.

Despite extensive research aimed at comprehending the etiopathogenesis of Alzheimer’s disease, only six drugs have been approved since 1996 for treatment. The rate of failure of drugs being developed for treating Alzheimer’s disease is alarming (~99.6%) and is even higher than that reported for cancer (~81%). Most of the existing therapeutic options have proven inadequate in arresting the progression of the disease and long-term management of associated symptoms. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to develop various types of disease-modifying interventions and drug/therapy candidates that offer symptomatic relief. In fact, multiple initiatives by start-ups are being backed by venture capital and other strategic investors. In the coming years, the market is anticipated to grow at a significant pace as more novel solutions clear clinical evaluation and get commercialized.

Key Topics Covered:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/8cmbd3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190502005754/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Alzheimer’s Disease Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/02/2019 01:54 PM/DISC: 05/02/2019 01:54 PM